Effects of ocular betaxolol on glucose and lipid metabolism after long-term treatment

Clinical Drug Investigation

Volumn 14, Issue 5, 1997, Pages 363-368

  Caccavale, Antonio ^a,c   Fusco, Rosa ^b   Romano, Beniamino ^b   Antinozzi, Paolo P ^b   Pignalosa, Giuseppe ^b  

^a Magenta Hospital   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGLAUCOMA AGENT; BETAXOLOL; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; TRIACYLGLYCEROL;

ADULT; ARTICLE; ATRIOVENTRICULAR CONDUCTION; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; INTRAOCULAR HYPERTENSION; LIPID METABOLISM; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TOPICAL DRUG ADMINISTRATION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0030685038     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199714050-00004     Document Type: Article

References (24)

1. Krone W, Nagele H. Effects of antihypertensives on plasma lipids and lipoprotein metabolism. Am Heart J 1988; 116: 1729-34
2. Woodstock BG, Rietbrock N. β-Blocker induced changes in the cholesterol: high-density lipoprotein cholesterol ratio and risk of coronary heart disease. Klin Wochenschr 1984; 62: 843-9
3. Wolinsky H. The effects of β-adrenergic blocking agents on blood lipid levels. Clin Cardiol 1987; 10: 561-6
4. Deacon SP, Karunanuyake A, Barnett D. Acebutolol, atenolol and propranolol and metabolic responses to acute hypoglycaemia in man. BMJ 1977; 2: 1255-7
5. Harvengt C, Heller FR. Short term effects of β-blockers atenolol, nadolol, pindolol and propranolol on lipoprotein metabolism in normolipemic subjects. J Clin Pharmacol 1987; 27: 475-80
6. Hunninghake DB. The effects of cardioselective vasodilating β-blockers on lipids. Am Heart J 1991; 121 (3 pt 2): 1029-32
7. Van Brummelen P. The relevance of intrinsic sympathomimetic activity for β-blocker induced changes in plasma lipids. J Cardiovasc Pharmacol 1483; 49: 551-5
8. Day JL, Metcalfe J, Simpson CN. Adrenergic mechanism in control of plasma lipid concentrations. BMJ 1982; 184: 1145-8
9. Frick NH, Elo O, Haapa D. Helsinky heart study, primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987; 317: 1237-45
10. Lipid Reasearch Clinics Program. The lipid research clinics coronary primary prevention trial - results I-II. JAMA 1984; 251: 351-74
11. Kaplan NM. Maximally reduced cardiovascular risk in the treatment of hypertension. Ann Internal Med 1988; 109: 36-40
12. MacMahon SW, Cutler JA, Furbery CD, et al. The effects of drug treatment for hypertension on morbidity and mortality from cardiovascular disease: a review of randomised controlled trials. Prog Cardiovasc Dis 1986; XXIX (3): Suppl.I: 99-118
13. Fraunfelder FT. Ocular beta-blockers and systemic effects. Arch Intern Med 1986; 146: 1073-4
14. Swenson ER. Severe hyperkalemia as a complication of timolol: a topically applied β-adrenergic antagonist. Arch Intern Med 1986; 146: 1220-1
15. Coleman AL, Diehl DL, Quigley HA. Topical timolol decrease plasma high-density lipoprotein cholesterol level. Arch Ophthalmol 1990; 108: 1260-3
16. Freedman SF, Freedman NJ, Shields MB, et al. Effects of ocular carteolol and timolol on plasma high-density lipoprotein cholesterol level. Am J Ophthalmol 1993; 116: 600-11
17. Manual of Laboratory Operations. Vol. 1. Lipids and lipoproteins Analysis. US Department of Health, Education and Welfare Publication (NHI) 1974; 75: 628
18. Kessler G, Lederer H. Fluorometric measurement of triglycerides. In: Skeggs LT, editor. Automation in analytical chemistry. Technicom Symposium. New York, NY: Mediac Inc. 1965: 341-4
19. Trinder P. God-Pap method in serum and plasma. Ann Clin Biochem 1969; 6: 24
20. Jaillard J, Rouffy J, Sauvanet JP. Long term influence of hetaxolol on plasma lipids and proteins. In: Morselli PL, et al., editors. Proceedings of the International Symposium on Betaxolol; Paris 1982, Laboratoires d'etudes de recherches Synthelab. New York, NY: Raven Press, 1983: 221-31
21. Djian J. Clinical evaluation of hetaxolol as a once-daily treatment for hypertension in 4685 patients. Br J Clin Pract 1985; 39: 188-91
22. Chamberlain TJ. Myocardial infarction after ophthalmic hetaxolol. N Engl J Med 1989; 321: 1342
23. Nelson WL, Kuritsky JN. Early postmarketing surveillance of hetaxolol hydrochloride. Am J Ophthalmol 1986; 103: 592
24. Weinreb RM, Van Buskirk EM, Cherniak R, et al. Long-term betaxolol therapy in glaucoma patients with pulmonary disease. Am J Ophthalmol 1988; 106: 162-7